Volume 9 Issue 6
Jun.  2018
Turn off MathJax
Article Contents
Yelei Guo, Kaichao Feng, Yao Wang, Weidong Han, Yelei Guo. Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment[J]. Protein&Cell, 2018, 9(6): 516-526. doi: 10.1007/s13238-017-0394-6
Citation: Yelei Guo, Kaichao Feng, Yao Wang, Weidong Han, Yelei Guo. Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment[J]. Protein&Cell, 2018, 9(6): 516-526. doi: 10.1007/s13238-017-0394-6

Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment

doi: 10.1007/s13238-017-0394-6
Funds:  This research was supported by the grants from the National Natural Science Foundation of China (Grant No. 81230061 to WDH), the Science and Technology Planning Project of Beijing City (No. Z151100003915076 to WDH), the National Key Research and Development Program of China (No. 2016YFC1303501 and 2016YFC1303504 to WDH), and the Nursery Innovation Fund (No. 15KMM50 to YLG).
More Information
  • Corresponding author: Weidong Han, hanwdrsw69@yahoo.com
  • Received Date: 2016-12-21
  • Accepted Date: 2017-02-23
  • Publish Date: 2018-01-01
  • Cancer stem cells (CSCs), a subpopulation of tumor cells, have self-renewal and multi-lineage differentiation abilities that play an important role in cancer initiation, maintenance, and metastasis. An accumulation of evidence indicates that CSCs can cause conventional therapy failure and cancer recurrence because of their treatment resistance and self-regeneration characteristics. Therefore, approaches that specifically and efficiently eliminate CSCs to achieve a durable clinical response are urgently needed. Currently, treatments with chimeric antigen receptor-modified T (CART) cells have shown successful clinical outcomes in patients with hematologic malignancies, and their safety and feasibility in solid tumors was confirmed. In this review, we will discuss in detail the possibility that CART cells inhibit CSCs by specifically targeting their cell surface markers, which will ultimately improve the clinical response for patients with various types of cancer. A number of viewpoints were summarized to promote the application of CSC-targeted CART cells in clinical cancer treatment. This review covers the key aspects of CSC-targeted CART cells against cancers in accordance with the premise of the model, from bench to bedside and back to bench.
  • loading
  • [1]
    Ades F, Yamaguchi N (2015) WHO, RECIST, and immune-related response criteria:is it time to revisit pembrolizumab results? Ecancermedicalscience 9:604
    Ahmed N, Brawley VS, Hegde M et al (2015) Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol 33:1688-1696
    Alamgeer M, Peacock CD, Matsui W et al (2013) Cancer stem cells in lung cancer:Evidence and controversies.Respirology 18:757-764
    Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988
    Ang W, Li Z, Chi Z et al (2017) Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis. Oncotarget. doi:10.18632/oncotarget.14592
    Baba T, Convery PA, Matsumura N et al (2009) Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28:209-218
    Bakalova R, Ohba H, Zhelev Z et al (2004) Quantum dots as photosensitizers? Nat Biotechnol 22:1360-1361
    Bidlingmaier S, Zhu X, Liu B (2008) The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med (Berl). 86:1025-1032
    Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730-737
    Bruce WR, Van Der Gaag HA (1963) Quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature 199:79-80
    Budde LE, Berger C, Lin Y et al (2013) Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS ONE 8:e82742
    Chao MP, Tang C, Pachynski RK et al (2011a) Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood 118:4890-4901
    Chao MP, Alizadeh AA, Tang C et al (2011b) Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res 71:1374-1384
    Chen Y, Song J, Jiang Y et al (2015) Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma. Int J Clin Exp Pathol 8:11287-11295
    Collins AT, Berry PA, Hyde C et al (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65:10946-10951
    Corbeil D, Marzesco AM, Wilsch-Brauninger M et al (2010) The intriguing links between prominin-1 (CD133), cholesterol-based membrane microdomains, remodeling of apical plasma membrane protrusions, extracellular membrane particles, and (neuro) epithelial cell differentiation. FEBS Lett 584:1659-1664
    Dai H, Zhang W, Li X et al (2015) Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia. Oncoimmunology 4:e1027469
    Deng Z, Wu Y, Ma W et al (2015) Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM. BMC Immunol 16:1
    Dragu DL, Necula LG, Bleotu C et al (2015) Therapies targeting cancer stem cells:Current trends and future challenges. World J Stem Cells 26:1185-1201
    Edris B, Weiskopf K, Volkmer AK et al (2012) Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA 109:6656-6661
    Feldmann G, Dhara S, Fendrich V et al (2007) Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases:a new paradigm for combinationtherapy in solid cancers. Cancer Res 67:2187-2196
    Feng K, Guo Y, Dai H et al (2016) Chimeric antigen receptormodified T cells for the immunotherapy of patients with EGFRexpressing advanced relapsed/refractory non-small cell lung cancer. Sci China Life Sci 59:468-479
    Feng K, Guo Y, Liu Y et al (2017) Cocktail treatment with EGFRspecific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma. J Hematol Oncol 10:4
    Focosi D, Bestagno M, Burrone O et al (2010) CD57+ T lymphocytes and functional immune deficiency. J Leukoc Biol 87:107-116
    Frank NY, Schatton T, Frank MH (2010) The therapeutic promise of the cancer stem cell concept. J Clin Invest 120:41-50
    Fukuda K, Saikawa Y, Ohashi M et al (2009) Tumor initiating potential of side population cells in human gastric cancer. Int J Oncol 34:1201-1207
    Garfall AL, Maus MV, Hwang WT et al (2015) Chimeric antigen receptor T cells against CD19 for multiple myeloma. N Engl J Med 373:1040-1047
    Ginestier C, Hur MH, Charafe-Jauffret E et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555-567
    Gires O, Klein CA, Baeuerle PA (2009) On the abundance of EpCAM on cancer stem cells. Nat Rev Cancer 9:143
    Grada Z, Hegde M, Byrd T et al (2013) TanCAR:a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids 2:e105
    Gross G, Waks T, Eshhar Z (1989) Expression of immunoglobulin-Tcell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:10024-10028
    Grupp SA, Kalos M, Barrett D et al (2013) Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N Engl J Med 368:1509-1518
    Gupta PB, Chaffer CL, Weinberg RA (2009) Cancer stem cells:mirage or reality? Nat Med 15:1010-1012
    Hemmati HD, Nakano I, Lazareff JA et al (2003) Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100:15178-15183
    Hibi K, Sakata M, Kitamura YH et al (2010) Demethylation of the CD133 gene is frequently detected in early gastric carcinoma. Anticancer Res 30:1201-1203
    Hodi FS, O'Day SJ, McDermott DF et al (2010) Improved survivalwith ipilimumab in patientswithmetastaticmelanoma. N Engl J Med 363:711-723
    Hong IS, Jang GB, Lee HY et al (2015) Targeting cancer stem cells by using the nanoparticles. Int J Nanomed 10(Spec Iss):251-260
    Hoos A, Eggermont AM, Janetzki S et al (2010) Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 102:1388-1397
    Hoos A, Wolchok JD, Humphrey RW et al (2015) CCR 20th anniversary commentary:immune-related response criteria-capturing clinical activity in immuno-oncology. Clin Cancer Res 21:4989-4991
    Jain A, Jain SK (2008) In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur J Pharm Sci 35:404-416
    Jain A, Jain SK, Ganesh N et al (2010) Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine 6:179-190
    Jensen MC, Riddell SR (2015) Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 33:9-15
    Julien S, Merino-Trigo A, Lacroix L et al (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18(19):5314-5328
    Kastan MB, Schlaffer E, Russo JE et al (1990) Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells. Blood 75:1947-1950
    Kershaw MH, Westwood JA, Darcy PK (2013) Gene-engineered T cells for cancer therapy. Nat Rev Cancer 13:525-541
    Khaleghi S, Rahbarizadeh F, Ahmadvand D et al (2012) A caspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing T cells. Int J Hematol 95:434-444
    Khan N, Mukhtar H (2015) Dietary agents for prevention and treatment of lung cancer. Cancer Lett 359:155-164
    Kim D, Wang J, Willingham SB et al (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26:2538-2545
    Kim MS, Ma JS, Yun H et al (2015) Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc 137:2832-2835
    Kochenderfer JN, Dudley ME, Kassim SH et al (2015) Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540-549
    Lamers CH, Sleijfer S, van Steenbergen S et al (2013) Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells:clinical evaluation and management of on-target toxicity. Mol Ther 21:904-912
    Lapidot T, Sirard C, Vormoor J et al (1994) A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367:645-648
    Lee DW, Gardner R, Porter DL et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188-195
    Li C, Heidt DG, Dalerba P et al (2007) Identification of pancreatic cancer stem cells. Cancer Res 67:1030-1037
    Lingala S, Cui YY, Chen X et al (2010) Immunohistochemical staining of cancer stem cell markers in hepatocellular carcinoma. Exp Mol Pathol 89:27-35
    Liu J, Jiang G (2006) CD44 and hematologic malignancies. Cell Mol Immunol 3:359-365
    Lu JW, Chang JG, Yeh KT et al (2011) Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem 113:833-838
    Ma S, Chan KW, Hu L et al (2007) Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132:2542-2556
    Ma ZL, Chen YP, Song JL et al (2015) Knock-down of CD24 inhibits proliferation, invasion and sensitizes breast cancer MCF-7 cells to tamoxifen in vitro. Eur Rev Med Pharmacol Sci 19:2394-2399
    Majeti R, Chao MP, Alizadeh AA et al (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286-299
    Marchitti SA, Brocker C, Stagos D et al (2008) Non-P450 aldehyde oxidizing enzymes:the aldehyde dehydrogenase superfamily. Expert Opin Drug Metab Toxicol 4:697-720
    Maude SL, Frey N, Shaw PA et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507
    Mitra M, Kandalam M, Verma RS et al (2010) Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma. Mol Vis 16:828-842
    Morgan RA, Yang JC, Kitano M et al (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18:843-851
    Munz M, Baeuerle PA, Gires O (2009) The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 69:5627-5629
    Naujokat C (2012) Targeting human cancer stem cells with monoclonal antibodies. J Clin Cell Immunol S5:7
    O'Brien CA, Pollett A, Gallinger S et al (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445:106-110
    Ogura E, Senzaki H, Yoshizawa K et al (1998) Immunohistochemical localization of epithelial glycoprotein EGP-2 and carcinoembryonic antigen in normal colonic mucosa and colorectal tumors. Anticancer Res 18:3669-3675
    Osta WA, Chen Y, Mikhitarian K et al (2004) EpCAM is overexpressed inbreast cancer and is a potential target for breast cancer gene therapy. Cancer Res 64:5818-5824
    Pan Q, Li Q, Liu S et al (2015) Concise review:targeting cancer stem cells using immunologic approaches. Stem Cells 33:2085-2092
    Porter DL, Levine BL, Kalos M et al (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733
    Rege TA, Hagood JS (2006) Thy-1 as a regulator of cell-cell and cellmatrix interactions in axon regeneration, apoptosis, adhesion, migration, cancer, and fibrosis. FASEB J 20:1045-1054
    Reya T, Morrison SJ, Clarke MF et al (2001) Stem cells, cancer, and cancer stem cells. Nature 414:105-111
    Ricci-Vitiani L, Lombardi DG, Pilozzi E et al (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445:111-115
    Rosfjord E, Lucas J, Li G et al (2014) Advances in patient-derived tumor xenografts:From target identification to predicting clinical response rates in oncology. Biochem Pharmacol 91(2):135-143
    Sadelain M, Brentjens R, Riviere I (2013) The basic principles of chimeric antigen receptor design. Cancer Discov 3:388-398
    Salomon J, Goulet O, Canioni D et al (2014) Genetic characterization of congenital tufting enteropathy:epcam associated phenotype and involvement of SPINT2 in the syndromic form. Hum Genet 133:299-310
    Savona MR, Malcovati L, Komrokji R et al (2015) An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (mds/mpn) in adults. Blood 125:1857-1865
    Schmidt M, Scheulen ME, Dittrich C et al (2010) An open-label, randomized phase Ⅱ study of adecatumumab, a fully human antiEpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol 21:275-282
    Shigdar S, Lin J, Yu Y, Pastuovic M et al (2011) RNA aptamer against a cancer stem cell marker epithelial cell adhesion molecule. Cancer Sci 102:991-998
    Shmelkov SV, St Clair R, Lyden D et al (2005) AC133/CD133/Prominin-1. Int J Biochem Cell Biol 37:715-719
    Skubitz AP, Taras EP, Boylan KL et al (2013) Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol 130:579-587
    Smith LM, Nesterova A, Ryan MC et al (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100-109
    Song G, Liao X, Zhou L et al (2004) HI44a, an anti-CD44 monoclonal antibody, induces differentiation and apoptosis of human acute myeloid leukemia cells. Leuk Res 28:1089-1096
    Song Y, Zhu Z, An Y et al (2013) Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal Chem 85:4141-4149
    Stewart BW, Wild C, International Agency for Research on Cancer and World Health Organization (2014) World cancer report 2014. International Agency for Research on Cancer WHO Press, Lyon, France/Geneva, Switzerland
    Strioga M, Pasukoniene V, Characiejus D (2011) CD8+ CD28- and CD8+CD57+ T cells and their role in health and disease. Immunology 134:17-32
    Su YJ, Lin WH, Chang YW et al (2015) Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties. Oncotarget 6:38029-38045
    Sukowati CH, Anfuso B, Torre G et al (2013) The expression of CD90/Thy-1 in hepatocellular carcinoma:an in vivo and in vitro study. PLoS ONE 8:e76830
    Swaminathan SK, Roger E, Toti U et al (2013) CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. J Control Release 171:280-287
    Tang KH, Dai YD, Tong M et al (2013) A CD90(+) tumor-initiating cell population with an aggressive signature and metastatic capacity in esophageal cancer. Cancer Res 73:2322-2332
    Till BG, Jensen MC, Wang J et al (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains:pilot clinical trial results. Blood 119:3940-3950
    Van der Gun BT, Melchers LJ, Ruiters MH et al (2010) EpCAM in carcinogenesis:the good, the bad or the ugly. Carcinogenesis 31:1913-1921
    Visus C, Wang Y, Lozano-Leon A et al (2011) Targeting ALDH bright human carcinoma-initiating cells with ALDH1A1-Specific CD8+ T cells. Clin Cancer Res 17:6174-6184
    Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours:accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768
    Wang L, Su W, Liu Z et al (2012) CD44 antibody-targeted liposomal nanoparticles for molecular imaging and therapy of hepatocellular carcinoma. Biomaterials 33:5107-5114
    Wang Y, Zhang WY, Han QW et al (2014) Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptormodified T cells. Clin Immunol 155:160-175
    Wang QS, Wang Y, Lv HY et al (2015a) Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia. Mol Ther 23:184-191
    Wang X, Liu Y, Zhou K et al (2015b) Isolation and characterization of CD105+/CD90+ subpopulation in breast cancer MDA-MB-231 cell line. Int J Clin Exp Pathol 8:5105-5112
    Willingham SB, Volkmer JP, Gentles AJ et al (2012) The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA 109:6662-6667
    Wolchok JD, Hoos A, O'Day S et al (2009) Guidelines for the evaluation of immune therapy activity in solid tumors:immunerelated response criteria. Clin Cancer Res 15:7412-7420
    Woo SR, Oh YT, An JY et al (2015) Glioblastoma specific antigens, GD2 and CD90, are not involved in cancer stemness. Anat Cell Biol 48:44-53
    Wu RC, Liu S, Chacon JA et al (2012) Detection and characterization of a novel subset of CD8(+) CD57(+) T cells in metastatic melanoma with an incompletely differentiated phenotype. Clin Cancer Res 18:2465-2477
    Wu CY, Roybal KT, Puchner EM et al (2015) Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 350:4077
    Yamashita T, Wang XW (2013) Cancer stem cells in the development of liver cancer. J Clin Invest 123:1911-1918
    Yee C, Thompson JA, Byrd D et al (2002) Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma:in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci USA 99:16168-16173
    Yi JM, Tsai HC, Glöckner SC et al (2008) Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 68:8094-8103
    Yin AH, Miraglia S, Zanjani ED et al (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002-5012
    Zhang Q, Shi S, Yen Y et al (2010) A subpopulation of CD133(+) cancer stem-like cells characterized in human oral squamous cell carcinoma confer resistance to chemotherapy. Cancer Lett 289:151-160
    Zhang C, Zhou C, Wu XJ et al (2014a) Human CD133-positive hematopoietic progenitor cells initiate growth and metastasis of colorectal cancer cells. Carcinogenesis 35:2771-2777
    Zhang YH, Wang ZY, Hao FY et al (2014b) Cluster of differentiation 24 monoclonal antibody induces apoptosis in the osteosarcoma cells. Eur Rev Med Pharmacol Sci 18:2038-2041
    Zhao L, Yang Y, Zhou P et al (2015) Targeting CD133 high colorectal cancer cells in vitro and in vivo with an asymmetric bispecific antibody. J Immunother 38:217-228
    Zhu J, Thakolwiboon S, Liu X et al (2014) Overexpression of CD90(Thy-1) in pancreatic adenocarcinoma present in the tumor microenvironment. PLoS ONE 9:e115507
    Zhu X, Prasad S, Gaedicke S et al (2015) Patient-derived glioblastoma stem cells are killed by CD133-specific CAR T cells but induce the T cell aging marker CD57. Oncotarget 6:171-184
  • 加载中


    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (278) PDF downloads(2703) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint